3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
43
Carcinoma, Hepatocellular
19
Rectal Neoplasms
10
Colonic Neoplasms
10
Neoplasm Metastasis
9
Gastrointestinal Stromal Tumors
8
Sarcoma
5
Ovarian Neoplasms
5
Cholangiocarcinoma
5
Melanoma
4
Pancreatic Neoplasms
3
Osteosarcoma
3
Liver Neoplasms
3
Glioblastoma
3
Stomach Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Gallbladder Neoplasms
2
Fatigue
2
Esophageal Neoplasms
2
Colorectal Cancer Metastatic
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
1
Thyroid Neoplasms
1
Thymoma
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Interventions
Etoposide
78
Carboplatin
67
Cisplatin
46
durvalumab
26
Topotecan
26
atezolizumab
20
Radiotherapy
19
Irinotecan
19
Paclitaxel
17
anlotinib
16
apatinib
15
Nivolumab
15
Drug Therapy
12
pembrolizumab
9
Platinum
9
toripalimab
8
tislelizumab
8
Gemcitabine
8
Bevacizumab
8
Temozolomide
7
Radiosurgery
7
PM 01183
7
Ipilimumab
7
Pemetrexed
6
Docetaxel
6
Albumin-Bound Paclitaxel
6
olaparib
5
amrubicin
5
Sunitinib
5
surufatinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Small Cell Lung Carcinoma
×
regorafenib
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn